Rayan Kaedbey
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Journal: Nature medicine
Published: October 03, 2025
Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database.
Journal: Clinical lymphoma, myeloma & leukemia
Published: August 19, 2025
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 07, 2025
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma.
Journal: Current oncology (Toronto, Ont.)
Published: March 29, 2025
Failure of daratumumab in the treatment of anti-synthetase syndrome: A case report.
Journal: SAGE open medical case reports
Published: January 11, 2025
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 07, 2025
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada.
Journal: Clinical lymphoma, myeloma & leukemia
Published: November 11, 2024
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study.
Journal: Cancer medicine
Published: June 13, 2024
Recommendations for the effective use of T-cell-redirecting therapies: a Canadian consensus statement.
Journal: Frontiers in oncology
Published: June 10, 2024
Last Updated: 09/26/2026